Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
06/01/2026 14:14
Jan 6 (Reuters) - Transcode Therapeutics Inc RNAZ.O: TRANSCODE THERAPEUTICS INC - TTX-MC138 PHASE 2A CLINICAL TRIAL EXPECTED IN FIRST HALF OF 2026 - SEC FILING Source text: [ID:n0001104659-26-001097] Further company coverage: RNAZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors